LDHA and cancer: Furthermore, genetic deletion of LDHA, 2-DG administration, or mTORC1 inhibition has been proposed as therapeutic avenues designed to decrease glycolytic metabolism in cancer cells, reduce lactate in the TIME, and repolarize TAMs to a pro-inflammatory state (Vitale et al., 2019).